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doi:10.1016/j.jtcvs.2003.11.002Wijeysundera and colleagues1 retrospectively examined theeffects of preoperative calcium antagonists on operativemortality and postoperative morbidity after cardiac surgery.Results, including propensity score analysis, showed signif-icant reduction in operative mortality associated with use ofcalcium antagonists. Wijeysundera and colleagues1 con-
cluded that a large randomized trial of perioperative calcium antagonists is indicated
to test the hypothesis that calcium antagonists decrease perioperative morbidity and
mortality.
This study is important because it is the largest study to examine the effects of
calcium antagonists on perioperative mortality after cardiac surgery. The results are
also important in that the risks versus benefits of calcium antagonists in cardiac
patients remain controversial. The reduction in mortality was relatively large
(roughly 50%), again implying that these results could save many lives.
This study unfortunately represents the pinnacle of current cardiac surgical
research, a retrospective search for statistical associations. In this study, preopera-
tive use of calcium antagonists was statistically associated with lower perioperative
mortality. As Wijeysundera and colleagues1 admit, however, this retrospective
search for statistical association was complicated by the fact that the two treatment
groups were unmatched and may have been tainted by selection bias. Multivariable
propensity score analysis was therefore used, as perhaps the most sophisticated
statistical weapon in the cardiac surgical arsenal to attempt to correct for selection bias.
The problem is that association does not prove causality, even when propensity
score analysis is used. There are classic examples in both remote and recent medical
research of confusion between association and causality. Take, for example, the
autopsy study ridiculed by statisticians (but not all physicians) demonstrating an
inverse relationship between cancer and tuberculosis,2 with the conclusion that
tuberculosis prevents cancer. Take also, for example, the recent study (still often
quoted) showing a significant association between pulmonary artery catheter use
and hospital mortality in intensive care patients, with the conclusion that pulmonary
artery catheters kill patients.3,4
One important test for causality is to examine whether plausible mechanisms of
causality can be demonstrated. The difficulty finding a mechanism by which
tuberculosis prevents cancer should raise concerns.2 Similarly, the fact that pulmo-
nary artery catheters kill primarily by pulmonary artery rupture and ventricular
arrhythmia should raise concerns when, in fact, few patients dying after pulmonary
artery catheter use suffered either of these consequences.3,4
In the study of Wijeysundera and colleagues,1 it is similarly challenging to guess
how calcium antagonists might improve mortality associated with cardiac surgery.
Wijeysundera and colleagues1 propose the mechanism of preventing ischemia and
arrhythmias. Calcium antagonists are known to have value in treating hypertension,
angina, tachycardia, and possibly myocardial ischemia.5,6 However, calcium antag-
onists have been disappointing in failing to consistently prevent atrial fibrillation,
improve graft patency,7 or improve morbidity or mortality from heart failure or
coronary disease.8,9 Although effects vary with the type of calcium antagonist used,
calcium antagonists are relatively contraindicated in patients with bradycardia,
ventricular dysfunction, or hypotension. So how do calcium-channel blockers im-
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gation is clearly indicated, now may be too soon to recom-
mend more aggressive use of calcium antagonists before
cardiac surgery.
For infections, proof of causality requires satisfaction of
the Koch postulates. For noninfectious causality, proof ul-
timately means a prospective, randomized study. Achieving
such studies requires funding, however, and funding for
clinical research in cardiac surgery is remarkably absent.
Why? First, the National Heart, Lung and Blood Institute
decided nearly 15 years ago to invest federal dollars into
basic research rather than clinical research. This decision
may have been wise in the long run, but it has definite
short-term consequences. Second, the cardiac surgical mar-
ket is too small to be worth the investment for most private
corporations, such as the pharmaceutical industry and the
medical device industry. Because neither of these two fund-
ing problems is likely to change soon, cardiac surgeons
must make the best of what we have. The onus will always
remain on the reader and the responsible investigator not to
confuse association and causation.
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